$ASEP.c gains EU patent approval for SepsetER. This is a great read that identifies and supports Asep Medical’s (CSE: ASEP) market opportunity with its novel sepsis diagnostic tech.
Asep’s solution, SepsetER, identifies sepsis infection by detecting unique molecular signatures of sepsis-specific immune responses, rather than the presence of pathogens. This allows SespsetER to deliver reliable results in under an hour, which is staggering considering current testing methods take between 24-48 hours to deliver results.
The company recently received an official allowance of its patent claims in the EU, which opens up a huge market to the company. In addition to this, Asep plans to validate its patent in Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, and the UK.
$ASEP.c is currently trading at $.18, which looks like a huge discount to me considering these recent developments. The company is presently valued at $10.1 million.
https://www.hospimedica.com/critical-care/articles/294793393/blood-based-test-diagnoses-severe-sepsis-within-1-2-hours-of-er-admission.html